1887

Abstract

Purpose. The neutrophil-derived oxidant N-chlorotaurine (NCT) displays remarkable in vivo tolerability and efficacy against a range of pathogens. The aim of this study was to characterize the response of the pulmonary pathogen Aspergillus fumigatus to NCT.

Methodology. The effect of NCT on the growth and viability of A. fumigatus was characterized. NCT-induced alteration of amino acids and gliotoxin from A. fumigatus mycelium was assessed. Label-free shotgun quantitative proteomic analysis was performed on A. fumigatus exposed to NCT for 24 h.

Results. Incubation of A. fumigatus with NCT at concentrations ranging from 6.8 to 55 mM decreased conidial growth and viability, and mycelium biomass relative to the controls. Exposure to NCT (13.77 mM) resulted in increased amino acids and gliotoxin levels from A. fumigatus mycelium. Exposure of A. fumigatus mycelium to NCT (6.8 mM) revealed an enrichment in proteins associated with the ribosome, transcription and translation and non-ribosomal peptide biosynthesis (e.g. Pes1, Pes3), which play an essential role in oxidative stress resistance in A. fumigatus. A decrease in the abundance of proteins associated with fumagillin and pseurotin biosynthesis highlighted the anti-virulence activity of NCT.

Conclusion. These results indicate that NCT induces an oxidative stress response in A. fumigatus as evidenced by alterations in the proteome and inhibits conidial and mycelial growth. Clinical investigations of topical application of NCT to treat Aspergillus infections are encouraged.

Loading

Article metrics loading...

/content/journal/jmm/10.1099/jmm.0.000900
2018-12-13
2019-10-14
Loading full text...

Full text loading...

References

  1. Dagenais TR, Keller NP. Pathogenesis of Aspergillus fumigatus in Invasive Aspergillosis. Clin Microbiol Rev 2009;22:447–465 [CrossRef][PubMed]
    [Google Scholar]
  2. Margalit A, Kavanagh K. The innate immune response to Aspergillus fumigatus at the alveolar surface. FEMS Microbiol Rev 2015;39:670–687 [CrossRef][PubMed]
    [Google Scholar]
  3. Stevens DA, Moss RB, Kurup VP, Knutsen AP, Greenberger P et al. Allergic bronchopulmonary aspergillosis in cystic fibrosis-state of the art: Cystic Fibrosis Foundation Consensus Conference. Clin Infect Dis 2003;37:S225–S264 [CrossRef][PubMed]
    [Google Scholar]
  4. Chotirmall SH, Al-Alawi M, Mirkovic B, Lavelle G, Logan PM et al. Aspergillus-associated airway disease, inflammation, and the innate immune response. Biomed Res Int 2013;2013:1–14 [CrossRef][PubMed]
    [Google Scholar]
  5. Coméra C, André K, Laffitte J, Collet X, Galtier P et al. Gliotoxin from Aspergillus fumigatus affects phagocytosis and the organization of the actin cytoskeleton by distinct signalling pathways in human neutrophils. Microbes Infect 2007;9:47–54 [CrossRef][PubMed]
    [Google Scholar]
  6. Fallon JP, Reeves EP, Kavanagh K. Inhibition of neutrophil function following exposure to the Aspergillus fumigatus toxin fumagillin. J Med Microbiol 2010;59:625–633 [CrossRef][PubMed]
    [Google Scholar]
  7. Kwon-Chung KJ, Sugui JA. What do we know about the role of gliotoxin in the pathobiology of Aspergillus fumigatus?. Med Mycol 2009;47:S97–S103 [CrossRef][PubMed]
    [Google Scholar]
  8. Sugui JA, Pardo J, Chang YC, Zarember KA, Nardone G et al. Gliotoxin is a virulence factor of Aspergillus fumigatus: gliP deletion attenuates virulence in mice immunosuppressed with hydrocortisone. Eukaryot Cell 2007;6:1562–1569 [CrossRef][PubMed]
    [Google Scholar]
  9. Reeves EP, Reiber K, Neville C, Scheibner O, Kavanagh K et al. A nonribosomal peptide synthetase (Pes1) confers protection against oxidative stress in Aspergillus fumigatus. Febs J 2006;273:3038–3053 [CrossRef][PubMed]
    [Google Scholar]
  10. O'Hanlon KA, Cairns T, Stack D, Schrettl M, Bignell EM et al. Targeted disruption of nonribosomal peptide synthetase pes3 augments the virulence of Aspergillus fumigatus. Infect Immun 2011;79:3978–3992 [CrossRef][PubMed]
    [Google Scholar]
  11. Schaffner A, Douglas H, Braude A. Selective protection against conidia by mononuclear and against mycelia by polymorphonuclear phagocytes in resistance to Aspergillus. Observations on these two lines of defense in vivo and in vitro with human and mouse phagocytes. J Clin Invest 1982;69:617–631[PubMed]
    [Google Scholar]
  12. Mircescu MM, Lipuma L, van Rooijen N, Pamer EG, Hohl TM et al. Essential role for neutrophils but not alveolar macrophages at early time points following Aspergillus fumigatus infection. J Infect Dis 2009;200:647–656 [CrossRef][PubMed]
    [Google Scholar]
  13. Gazendam RP, van Hamme JL, Tool AT, Hoogenboezem M, van den Berg JM et al. Human Neutrophils Use Different Mechanisms To Kill Aspergillus fumigatus Conidia and Hyphae: Evidence from Phagocyte Defects. J Immunol 2016;196:1272–1283 [CrossRef][PubMed]
    [Google Scholar]
  14. Segal BH, Romani LR. Invasive aspergillosis in chronic granulomatous disease. Med Mycol 2009;47:S282–S290 [CrossRef][PubMed]
    [Google Scholar]
  15. Dennis CG, Greco WR, Brun Y, Youn R, Slocum HK et al. Effect of amphotericin B and micafungin combination on survival, histopathology, and fungal burden in experimental aspergillosis in the p47phox-/- mouse model of chronic granulomatous disease. Antimicrob Agents Chemother 2006;50:422–427 [CrossRef][PubMed]
    [Google Scholar]
  16. Klebanoff SJ. Myeloperoxidase: friend and foe. J Leukoc Biol 2005;77:598–625 [CrossRef][PubMed]
    [Google Scholar]
  17. Test ST, Lampert MB, Ossanna PJ, Thoene JG, Weiss SJ et al. Generation of nitrogen-chlorine oxidants by human phagocytes. J Clin Invest 1984;74:1341–1349 [CrossRef][PubMed]
    [Google Scholar]
  18. Zgliczyński JM, Stelmaszyńska T, Domański J, Ostrowski W. Chloramines as intermediates of oxidation reaction of amino acids by myeloperoxidase. Biochim Biophys Acta 1971;235:419–424 [CrossRef][PubMed]
    [Google Scholar]
  19. Grisham MB, Jefferson MM, Melton DF, Thomas EL. Chlorination of endogenous amines by isolated neutrophils. Ammonia-dependent bactericidal, cytotoxic, and cytolytic activities of the chloramines. J Biol Chem 1984;259:10404–10413[PubMed]
    [Google Scholar]
  20. Weiss SJ, Klein R, Slivka A, Wei M et al. Chlorination of Taurine by Human Neutrophils. J Clin Invest 1982;70:598–607 [CrossRef]
    [Google Scholar]
  21. Gottardi W, Nagl M. N-chlorotaurine, a natural antiseptic with outstanding tolerability. J Antimicrob Chemother 2010;65:399–409 [CrossRef][PubMed]
    [Google Scholar]
  22. Nagl M, Hess MW, Pfaller K, Hengster P, Gottardi W et al. Bactericidal activity of micromolar N-chlorotaurine: evidence for its antimicrobial function in the human defense system. Antimicrob Agents Chemother 2000;44:2507–2513 [CrossRef][PubMed]
    [Google Scholar]
  23. Witko-Sarsat V, Delacourt C, Rabier D, Bardet J, Nguyen AT et al. Neutrophil-derived long-lived oxidants in cystic fibrosis sputum. Am J Respir Crit Care Med 1995;152:1910–1916 [CrossRef][PubMed]
    [Google Scholar]
  24. Marcinkiewicz J, Kontny E. Taurine and inflammatory diseases. Amino Acids 2014;46:7–20 [CrossRef][PubMed]
    [Google Scholar]
  25. Weiss SJ. Tissue destruction by neutrophils. N Engl J Med 1989;320:365–376 [CrossRef][PubMed]
    [Google Scholar]
  26. Gruber M, Moser I, Nagl M, Lackner M. Bactericidal and fungicidal activity of n-chlorotaurine is enhanced in cystic fibrosis sputum medium. Antimicrob Agents Chemother 2017;61:e0252716 [CrossRef][PubMed]
    [Google Scholar]
  27. Nagl M, Teuchner B, Pöttinger E, Ulmer H, Gottardi W et al. Tolerance of N-chlorotaurine, a new antimicrobial agent, in infectious conjunctivitis - a phase II pilot study. Ophthalmologica 2000;214:111–114 [CrossRef][PubMed]
    [Google Scholar]
  28. Neher A, Nagl M, Appenroth E, Gstöttner M, Wischatta M et al. Acute otitis externa: efficacy and tolerability of N-chlorotaurine, a novel endogenous antiseptic agent. Laryngoscope 2004;114:850–854 [CrossRef][PubMed]
    [Google Scholar]
  29. Nagl M, Gruber A, Fuchs A, Lell CP, Lemberger EM et al. Impact of N-chlorotaurine on viability and production of secreted aspartyl proteinases of Candida spp. Antimicrob Agents Chemother 2002;46:1996–1999 [CrossRef][PubMed]
    [Google Scholar]
  30. Reeves EP, Nagl M, O'Keeffe J, Kelly J, Kavanagh K et al. Effect of N-chlorotaurine on Aspergillus, with particular reference to destruction of secreted gliotoxin. J Med Microbiol 2006;55:913–918 [CrossRef][PubMed]
    [Google Scholar]
  31. Lackner M, Binder U, Reindl M, Gönül B, Fankhauser H et al. N-Chlorotaurine exhibits fungicidal activity against therapy-refractory scedosporium species and lomentospora prolificans. Antimicrob Agents Chemother 2015;59:6454–6462 [CrossRef][PubMed]
    [Google Scholar]
  32. Nagl M, Hengster P, Semenitz E, Gottardi W. The postantibiotic effect of N-chlorotaurine on Staphylococcus aureus. Application in the mouse peritonitis model. J Antimicrob Chemother 1999;43:805–809 [CrossRef][PubMed]
    [Google Scholar]
  33. Mustedanagic J, Ximenes VF, Nagl M. Microbicidal activity of N-chlorotaurine in combination with hydrogen peroxide. AMB Express 2017;7:102 [CrossRef][PubMed]
    [Google Scholar]
  34. Williams D, Kadaria D, Sodhi A, Fox R, Williams G et al. Chronic granulomatous disease presenting as Aspergillus fumigatus pneumonia in a previously healthy young woman. Am J Case Rep 2017;18:351–354 [CrossRef][PubMed]
    [Google Scholar]
  35. Levitz SM, Diamond RD. Mechanisms of resistance of Aspergillus fumigatus Conidia to killing by neutrophils in vitro. J Infect Dis 1985;152:33–42 [CrossRef][PubMed]
    [Google Scholar]
  36. Gottardi W, Nagl M. Chemical properties of N-chlorotaurine sodium, a key compound in the human defence system. Arch Pharm 2002;335:411–421 [CrossRef][PubMed]
    [Google Scholar]
  37. Sheehan G, Bergsson G, Mcelvaney NG, Reeves EP, Kavanagh K et al. The human cathelicidin antimicrobial peptide LL-37 promotes the growth of the pulmonary pathogen Aspergillus fumigatus. Infect Immun 2018;IAI.00097–18 [CrossRef][PubMed]
    [Google Scholar]
  38. Cox J, Neuhauser N, Michalski A, Scheltema RA, Olsen JV et al. Andromeda: a peptide search engine integrated into the MaxQuant environment. J Proteome Res 2011;10:1794–1805 [CrossRef][PubMed]
    [Google Scholar]
  39. Nierman WC, Pain A, Anderson MJ, Wortman JR, Kim HS et al. Genomic sequence of the pathogenic and allergenic filamentous fungus Aspergillus fumigatus. Nature 2005;438:1151–1156 [CrossRef][PubMed]
    [Google Scholar]
  40. Priebe S, Linde J, Albrecht D, Guthke R, Brakhage AA et al. FungiFun: a web-based application for functional categorization of fungal genes and proteins. Fungal Genet Biol 2011;48:353–358 [CrossRef][PubMed]
    [Google Scholar]
  41. Côté RG, Griss J, Dianes JA, Wang R, Wright JC et al. The PRoteomics IDEntification (PRIDE) Converter 2 framework: an improved suite of tools to facilitate data submission to the PRIDE database and the ProteomeXchange consortium. Mol Cell Proteomics 2012;11:1682–1689 [CrossRef][PubMed]
    [Google Scholar]
  42. Snelders E, Huis In 't Veld RA, Rijs AJ, Kema GH, Melchers WJ et al. Possible environmental origin of resistance of Aspergillus fumigatus to medical triazoles. Appl Environ Microbiol 2009;75:4053–4057 [CrossRef][PubMed]
    [Google Scholar]
  43. Fraczek MG, Bromley M, Bowyer P. An improved model of the Aspergillus fumigatus CYP51A protein. Antimicrob Agents Chemother 2011;55:2483–2486 [CrossRef][PubMed]
    [Google Scholar]
  44. Lazzarini C, Esposto MC, Prigitano A, Cogliati M, de Lorenzis G et al. Azole resistance in Aspergillus fumigatus clinical isolates from an italian culture collection. Antimicrob Agents Chemother 2016;60:682–685 [CrossRef][PubMed]
    [Google Scholar]
  45. Johnson MD, Perfect JR. Use of antifungal combination therapy: agents, order, and timing. Curr Fungal Infect Rep 2010;4:87–95 [CrossRef][PubMed]
    [Google Scholar]
  46. Gottardi W, Debabov D, Nagl M. N-chloramines, a promising class of well-tolerated topical anti-infectives. Antimicrob Agents Chemother 2013;57:1107–1114 [CrossRef][PubMed]
    [Google Scholar]
  47. Nagl M, Arnitz R, Lackner M. N-Chlorotaurine, a Promising Future Candidate for Topical Therapy of Fungal Infections. Mycopathologia 2018;183:161–170 [CrossRef][PubMed]
    [Google Scholar]
  48. Gottardi W, Nagl M. Active halogen compounds and proteinaceous material: loss of activity of topical anti-infectives by halogen consumption. J Pharm Pharmacol 2013;65:213–218 [CrossRef][PubMed]
    [Google Scholar]
  49. Nagl M, Lass-Flörl C, Neher A, Gunkel A, Gottardi W et al. Enhanced fungicidal activity of N-chlorotaurine in nasal secretion. J Antimicrob Chemother 2001;47:871–874 [CrossRef][PubMed]
    [Google Scholar]
  50. Gottardi W, Nagl M. Chlorine covers on living bacteria: the initial step in antimicrobial action of active chlorine compounds. J Antimicrob Chemother 2005;55:475–482 [CrossRef][PubMed]
    [Google Scholar]
  51. Marcinkiewicz J, Czajkowska B, Grabowska A, Kasprowicz A, Kociszewska B et al. Differential effects of chlorination of bacteria on their capacity to generate NO, TNF-alpha and IL-6 in macrophages. Immunology 1994;83:611–616[PubMed]
    [Google Scholar]
  52. Thati B, Noble A, Rowan R, Creaven BS, Walsh M et al. Mechanism of action of coumarin and silver(I)-coumarin complexes against the pathogenic yeast Candida albicans. Toxicol In Vitro 2007;21:801–808 [CrossRef][PubMed]
    [Google Scholar]
  53. Kelly J, Kavanagh K. Proteomic analysis of proteins released from growth-arrested Candida albicans following exposure to caspofungin. Med Mycol 2010;48:598–605 [CrossRef][PubMed]
    [Google Scholar]
  54. Reeves EP, Murphy T, Daly P, Kavanagh K. Amphotericin B enhances the synthesis and release of the immunosuppressive agent gliotoxin from the pulmonary pathogen Aspergillus fumigatus. J Med Microbiol 2004;53:719–725 [CrossRef][PubMed]
    [Google Scholar]
  55. Johnston MD, Hanlon GW, Denyer SP, Lambert RJ. Membrane damage to bacteria caused by single and combined biocides. J Appl Microbiol 2003;94:1015–1023 [CrossRef][PubMed]
    [Google Scholar]
  56. Eshwika A, Kelly J, Fallon JP, Kavanagh K. Exposure of Aspergillus fumigatus to caspofungin results in the release, and de novo biosynthesis, of gliotoxin. Med Mycol 2013;51:121–127 [CrossRef][PubMed]
    [Google Scholar]
  57. Shenton D, Smirnova JB, Selley JN, Carroll K, Hubbard SJ et al. Global translational responses to oxidative stress impact upon multiple levels of protein synthesis. J Biol Chem 2006;281:29011–29021 [CrossRef][PubMed]
    [Google Scholar]
  58. Mccowen MC, Callender ME, Lawlis JF. Fumagillin (H-3), a New antibiotic with amebicidal properties. Science 1951;113:202–203 [CrossRef][PubMed]
    [Google Scholar]
  59. Amitani R, Murayama T, Nawada R, Lee WJ, Niimi A et al. Aspergillus culture filtrates and sputum sols from patients with pulmonary aspergillosis cause damage to human respiratory ciliated epithelium in vitro. Eur Respir J 1995;8:1681–1687 [CrossRef]
    [Google Scholar]
  60. Fallon JP, Reeves EP, Kavanagh K. The Aspergillus fumigatus toxin fumagillin suppresses the immune response of Galleria mellonella larvae by inhibiting the action of haemocytes. Microbiology 2011;157:1481–1488 [CrossRef][PubMed]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jmm/10.1099/jmm.0.000900
Loading
/content/journal/jmm/10.1099/jmm.0.000900
Loading

Data & Media loading...

Supplementary File 1

PDF
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error